JAZZ · Jazz Pharmaceuticals plc
$205.70
-3.88% last session
End-of-day data · close of 2026-10-26
Market cap
$13B
Enterprise value
$16B
Trailing P/E
14.1
Forward P/E
7.9
Dividend yield
0.0%
Beta
0.37
Avg volume
1M
Employees
3K
Daily Change %
-3.88%
5 Days Change
-4.17%
10 Days Change
-2.15%
30 Days Change
-13.55%
60 Days Change
-15.88%
Month to Day Change
-11.72%
Year to Day Change
21.00%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — JAZZ
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-21
Latest call per bank · past 12 months
Morgan Stanley
Overweight$314
+52.6% vs priceRBC Capital
Outperform$296
+43.9% vs priceCitigroup
Buy$325
+58.0% vs priceUBS
Buy$337
+63.8% vs priceBarclays
Overweight$271
+31.7% vs priceDeutsche Bank
Buy$300
+45.8% vs priceJP Morgan
Overweight$276
+34.2% vs priceWells Fargo
Overweight$300
+45.8% vs priceBank of America
Buy$307
+49.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Morgan Stanley | Maintains | Overweight | $322 → $314 |
| 2026-10-08 | RBC Capital | Maintains | Outperform | $299 → $296 |
| 2026-10-07 | Truist Securities | Maintains | Buy | $281 → $286 |
| 2026-09-30 | Citigroup | Initiates | Buy | $0.00 → $325 |
| 2026-09-11 | UBS | Maintains | Buy | $315 → $337 |
| 2026-09-10 | Barclays | Maintains | Overweight | $270 → $271 |
| 2026-08-26 | Deutsche Bank | Maintains | Buy | $287 → $300 |
| 2026-08-26 | Morgan Stanley | Maintains | Overweight | $283 → $322 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 30 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 12.6% below the 50-day MA ($235.29).
- bearish: Price vs 200-day MA: Trading 4.7% below the 200-day MA ($215.74).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.18) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($131.16) and high ($261.62).
JAZZ Price Chart
Loading chart for JAZZ…
Fundamentals
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.